0000856982-23-000035.txt : 20230608 0000856982-23-000035.hdr.sgml : 20230608 20230607181443 ACCESSION NUMBER: 0000856982-23-000035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230607 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20230608 DATE AS OF CHANGE: 20230607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIT MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0000856982 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870447695 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-18592 FILM NUMBER: 231000181 BUSINESS ADDRESS: STREET 1: 1600 WEST MERIT PARK WAY CITY: SOUTH JORDAN STATE: UT ZIP: 84095 BUSINESS PHONE: 8012531600 MAIL ADDRESS: STREET 1: 1600 WEST MERIT PARKWAY CITY: SOUTH JORDAN STATE: UT ZIP: 84095 8-K 1 mmsi-20230607x8k.htm 8-K
0000856982falseMERIT MEDICAL SYSTEMS INC00008569822023-06-072023-06-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 7, 2023

Graphic

Merit Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Utah

    

0-18592

    

87-0447695

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation or organization)

File Number)

Identification No.)

1600 West Merit Parkway

    

South Jordan, Utah

84095

(Address of principal executive offices)

(Zip Code)

(801) 253-1600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, no par value

MMSI

NASDAQ Global Select Market System

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company        

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The information included in this Current Report contains forward-looking statements about Merit Medical Systems, Inc., a Utah corporation (“Merit”), that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. All statements included in this Current Report, other than statements of historical facts, are forward-looking statements for purposes of these provisions. These statements involve known and unknown risks, uncertainties and other factors that may cause Merit’s actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by the forward-looking statements, including those described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2022 and Merit’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, and subsequent filings with the SEC. In some cases, forward-looking statements can be identified by the use of terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “potential,” “project,” “will,” “would,” “seek,” “should,” “could,” “can,” “predict,” “potential,” “continue,” “objective” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain such identifying words.

All forward-looking statements included in this Current Report speak only as of the date made, are based on information available to Merit as of such date, and are subject to change. Merit assumes no obligation to update or revise any forward-looking statement. If Merit does update or correct one or more forward-looking statements, readers should not conclude that Merit will make additional updates or corrections. Merit’s actual results will likely differ, and may differ materially, from anticipated results. Readers should not unduly rely on any such forward-looking statements.

Item 1.01.   Entry into Material Definitive Agreement.

Merit entered into the Fourth Amended and Restated Credit Agreement on June 6, 2023 (the “Fourth Amended Credit Agreement”) with certain lenders identified therein (each a “Lender,” and collectively with other lenders from time to time party thereto, the “Lenders”), Wells Fargo Bank, National Association (the “Agent”), as Administrative Agent, Swingline Lender and a Lender, Wells Fargo Securities, LLC, BOFA Securities, Inc., HSBC Bank USA, National Association, U.S. Bank National Association and Truist Securities, Inc., as Joint Lead Arrangers and Joint Bookrunners, and Bank of America, N.A., HSBC Bank USA, National Association, U.S Bank National Association and Truist Bank as Co-Syndication Agents and TD Bank, N.A., as Documentation Agent. In addition to Wells Fargo Bank, National Association, Bank of America, N.A., HSBC Bank USA, National Association, U.S. Bank National Association, Truist Bank, TD Bank, Huntington Bank and Regions Bank are parties to the Fourth Amended Credit Agreement as Lenders. Pursuant to the terms of the Fourth Amended Credit Agreement, the Lenders have agreed to make a term loan in the amount of $150,000,000 and revolving credit loans up to an aggregate amount of up to $700,000,000, inclusive of sub-facilities of up to $40,000,000 for multicurrency borrowings, up to $40,000,000 for standby letters of credit and up to $30,000,000 for swingline loans from time to time.

On June 6, 2028, all principal, interest and other amounts outstanding under the Fourth Amended Credit Agreement are payable in full. At any time prior to the maturity date, Merit may repay any amounts owing under all revolving credit loans and all swingline loans in whole or in part, without premium or penalty; breakage fees are payable upon prepayment of Eurocurrency Rate (as defined in the Fourth Amended Credit Agreement) and Term SOFR Loans (as defined in the Fourth Amended Credit Agreement). Term loans made under the Fourth Amended Credit Agreement bear interest, at the election of Merit, at either (i) the Base Rate (as defined in the Fourth Amended Credit Agreement) plus the Applicable Margin (as defined in the Fourth Amended Credit Agreement) or, (ii) Adjusted Term SOFR (as defined in the Fourth Amended Credit Agreement) plus the Applicable Margin (as defined in the Fourth Amended Credit Agreement) and revolving credit loans bear interest, at the election of Merit, at either (a) the Base Rate plus the Applicable Margin, (b) Adjusted Term SOFR plus the Applicable Margin, (c) Adjusted Eurocurrency Rate plus the Applicable Margin and (d) Adjusted Daily Simple

2

SONIA (as defined in the Fourth Amended Credit Agreement) plus the Applicable Margin. Swingline loans bear interest at the Base Rate plus the Applicable Margin. Interest on each loan featuring the Base Rate and each Daily Simple SONIA Loan is due and payable on the last business day of each calendar quarter commencing June 30, 2023; interest on each loan featuring the Eurocurrency Rate and each Term SOFR Loan is due and payable on the last day of each interest period applicable thereto, and if such interest period extends over three months, at the end of each three-month interval during such interest period.

The Fourth Amended Credit Agreement contains covenants, representations, warranties and other terms customary for revolving credit loans of this nature. In this regard, the Fourth Amended Credit Agreement requires Merit to not, among other things, (a) permit the Consolidated Total Net Leverage Ratio (as defined in the Fourth Amended Credit Agreement) to be greater than 4.0 to 1.0 on the last day of any fiscal quarter (however, Merit may elect, in connection with a Permitted Acquisition (as defined in the Fourth Amended Credit Agreement) to increase the Consolidated Total Net Leverage Ratio to 4.5 to 1.0 for the fiscal quarter in which such Permitted Acquisition is consummated and the three consecutive quarterly test periods thereafter) or (b) permit the Consolidated Interest Coverage Ratio (as defined in the Fourth Amended Credit Agreement) as of the last day of any fiscal quarter to be less than 3.0 to 1.0.

Under the Fourth Amended Credit Agreement, upon the occurrence of an Event of Default (as defined in the Fourth Amended Credit Agreement), Merit may be required to repay all outstanding indebtedness immediately. An Event of Default is defined as, among other things, (a) a default in payment of principal of loans or reimbursement obligations, (b) a default by any credit party under the Fourth Amended Credit Agreement  (a “Credit Party”) in the payment of interest on any loans or reimbursement obligations, (c) any representation, warranty, certification or statement of fact in the Fourth Amended Credit Agreement or any other loan documents proves to have been materially incorrect or misleading when made, (d) any Credit Party defaults in performance of certain covenants or agreements set forth in the Fourth Amended Credit Agreement, (e) any Credit Party defaults in the payment of other indebtedness that exceeds $25,000,000, (f) any Change in Control (as defined in the Fourth Amended Credit Agreement) shall occur, (g) any Credit Party voluntarily or involuntarily enters into a bankruptcy proceeding, subject to certain conditions and other default provisions customary in similar type agreements.

If an Event of Default occurs, then, to the extent permitted in the Fourth Amended Credit Agreement, the Lenders may direct the Agent to, or the Agent may, with the consent of the Lenders holding more than 50% of the aggregate outstanding principal amount of the loans, as applicable, terminate the revolving credit commitment provided under the Fourth Amended Credit Agreement, accelerate the repayment of the outstanding loans and exercise all rights and remedies available to such Lenders under the Fourth Amended Credit Agreement and applicable law. In the case of an Event of Default that exists due to the occurrence of certain involuntary or voluntary bankruptcy, insolvency or reorganization events of Merit, the credit facility will automatically terminate and repayment of any outstanding loans shall be automatically accelerated.

As of the date hereof, Merit has borrowed approximately $242 million under the Fourth Amended Credit Agreement. Merit used borrowings under the Fourth Amended Credit Agreement to refinance the outstanding indebtedness under its Third Amended and Restated Credit Agreement, dated as of July 31, 2019, as amended from time to time prior to the date hereof, and to pay fees, commissions and expenses incurred in the initial borrowings and other extensions of credit under the Fourth Amended Credit Agreement.

The foregoing summary of the principal terms of the Fourth Amended Credit Agreement is not complete and is qualified in its entirety by the actual terms and conditions of that agreement, a copy of which Merit intends to file in a future filing with the SEC. The representations, warranties, and other terms contained in the Fourth Amended Credit Agreement were made solely for the purposes of such agreement and as of specified dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. Those representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Fourth Amended Credit Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Fourth

3

Amended Credit Agreement and should not rely on the representations, warranties or covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Merit or any of its respective subsidiaries or affiliates. Accordingly, investors should not rely on the representations and warranties as characterizations of the actual state of facts, since (i) they were made only as of the date of the Fourth Amended Credit Agreement or prior, specified dates, (ii) in some cases they are subject to qualifications with respect to materiality, knowledge and/or other matters, and (iii) they may be modified by the underlying exhibits and schedules.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth above under Item 1.01 related to Merit entering into the Fourth Amended and Restated Credit Agreement, dated June 6, 2023, is incorporated by reference into this Item 2.03.

Item 7.01.  Regulation FD Disclosure.

On June 7, 2023, Merit issued the attached press release (Exhibit 99.1) announcing entry into the Fourth Amended and Restated Credit Agreement.

The information contained in this Item 7.01 of this Current Report on Form 8-K (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01.  Financial Statements and Exhibits.

(d)Exhibits

EXHIBIT NUMBER

DESCRIPTION

99.1

Press Release, dated June 7, 2023, entitled “Merit Medical Announces New Five-Year Senior Secured Credit Agreement”.

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

4

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERIT MEDICAL SYSTEMS, INC.

Date: June 7, 2023

By:

/s/ Brian G. Lloyd

Brian G. Lloyd

Chief Legal Officer and Corporate Secretary

5

EX-99.1 2 mmsi-20230607xex99d1.htm EX-99.1

Merit Medical Announces New Five-Year Senior Secured Credit Agreement

Credit agreement includes a revolving credit facility of up to $700 million and a term loan facility of up to $150 million

SOUTH JORDAN, Utah, June 7, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that it has entered into a new, five-year senior secured credit agreement. The credit agreement includes a revolving credit facility in an aggregate principal amount of up to $700 million and a term loan facility in an aggregate principal amount of up to $150 million. Wells Fargo Bank, National Association is acting as administrative agent for a group of financial institutions providing the new credit facilities. Merit has borrowed approximately $242 million under the new credit facilities and intends to use the proceeds for general corporate purposes and the repayment of outstanding borrowings on its previous senior secured term loan and revolving credit facility. As a result, Merit's total indebtedness remains substantially unchanged following the execution of the new credit agreement.

“Wells Fargo Bank has been a trusted partner for Merit Medical and we appreciate their continued support, as well as our continuing group of lenders and the new banks that chose to participate, in this new credit agreement,” said Raul Parra, Merit Medical’s Chief Financial Officer. “This new credit agreement enhances our balance sheet and financial condition by extending our revolving credit facility and debt maturities. It also increases our financial flexibility and, combined with our improving profitability and free cash flow generation, gives us a solid foundation to support our growth initiatives.”

The new credit facilities are scheduled to mature on June 6, 2028. The terms of the new credit agreement are substantially consistent with Merit’s existing credit agreement. Additional details on the new credit agreement are outlined in Merit’s Current Report on Form 8-K filed with the Securities and Exchange Commission.

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,100 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.


CONTACTS 

PR/Media Inquiries 
Sarah Comstock 
Merit Medical 
+1-801-432-2864 | sarah.comstock@merit.com

INVESTOR INQUIRIES 
Mike Piccinino, CFA, IRC 
Westwicke - ICR 
+1-443-213-0509 | mike.piccinino@westwicke.com 


GRAPHIC 3 mmsi-20230607x8k001.jpg GRAPHIC begin 644 mmsi-20230607x8k001.jpg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end EX-101.SCH 4 mmsi-20230607.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mmsi-20230607_lab.xml EX-101.LAB EX-101.PRE 6 mmsi-20230607_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 07, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jun. 07, 2023
Entity File Number 0-18592
Entity Registrant Name MERIT MEDICAL SYSTEMS INC
Entity Incorporation, State or Country Code UT
Entity Tax Identification Number 87-0447695
Entity Address, Address Line One 1600 West Merit Parkway
Entity Address, City or Town South Jordan
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84095
City Area Code 801
Local Phone Number 253-1600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, no par value
Trading Symbol MMSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000856982
Amendment Flag false
XML 8 mmsi-20230607x8k_htm.xml IDEA: XBRL DOCUMENT 0000856982 2023-06-07 2023-06-07 0000856982 false MERIT MEDICAL SYSTEMS INC 8-K 2023-06-07 UT 0-18592 87-0447695 1600 West Merit Parkway South Jordan UT 84095 801 253-1600 false false false false Common Stock, no par value MMSI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - mmsi-20230607x8k.htm 9 mmsi-20230607x8k.htm mmsi-20230607.xsd mmsi-20230607_lab.xml mmsi-20230607_pre.xml mmsi-20230607xex99d1.htm mmsi-20230607x8k001.jpg http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mmsi-20230607x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "mmsi-20230607x8k.htm" ] }, "labelLink": { "local": [ "mmsi-20230607_lab.xml" ] }, "presentationLink": { "local": [ "mmsi-20230607_pre.xml" ] }, "schema": { "local": [ "mmsi-20230607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mmsi", "nsuri": "http://www.meritmedical.com/20230607", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "mmsi-20230607x8k.htm", "contextRef": "Duration_6_7_2023_To_6_7_2023_5ZT-DhnWV0mqRQrv4cTWXw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "mmsi-20230607x8k.htm", "contextRef": "Duration_6_7_2023_To_6_7_2023_5ZT-DhnWV0mqRQrv4cTWXw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000856982-23-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000856982-23-000035-xbrl.zip M4$L#!!0 ( -61QU9U;<6#=@, %H, 1 ;6US:2TR,#(S,#8P-RYX MH C2'M#;F.VUHD=K"=M?OW7+MQ MVJ1)UB%X:NIS?.[QO;XWF5WM\@P]4:F8X',O#B(/44Y$ROAZ[I7*QXHPYEU= MOGTS>^?[C]?W"Y0*4N:4:T0DQ9JF:,OT!CV(HL X%,T#M^'292,T&0Z&DTOQNC;7=4%9C0N;?1NIB&X7:[#7(JFPEI+MBPU_2QD?D-7N,PT)(7_+G%F#4"N,FI2T2 Y!1R6E ME' 7G[O3X="&C5W6ZV(4/BX8_^68'#.BNI4M=)*]GFS44&,#$277LL_Y'FRF M6\M>YY,0T",KG28::AD<=" 1!EY"%SHZW9%-MU6#M!+JZF0QIT3M=F2@RDR]0CK&BU&UW('CN - *TSKC3F MA!YW !NH3IN?YZTP Q.KJBGX4^TE\F%V%I.2UCG8!KO!Q/SX+6"D'VQ8,Z%MJFS:VZU*!A?B6H)%DT_3(WW!T@8,@\_ M[F^'BVE/>E.]8MWO!YY^XIKIYUN0E[D-["$&:3Z+61MREE*Z8IQ9^Q$D+$(^ M<@+'CYBG:*^&CN1F85NC+5_"&_XKO[3/4&<%6G:G&<#5[HHRM!,R0LKL+S8> MG/7OJU9=;5HEF[%OP)QPW@0CF* MT1_H=5OL=H:JP$X"2W*BY?(/4$L#!!0 ( -61 MQU81D>KU:04 .P[ 5 ;6US:2TR,#(S,#8P-U]L86(N>&ULU9OA;^(V M&,:_3]K_\(Y]V:0+*:"[J:CMJ>5Z)S1Z10?33INF4T@,6$MLY)@"__WL)$Y) M:@ZU+]J7X#B9QYT7BW,H@<2LV^[DE4'F1TD?WKF_N=V+;@\N^[U>_^T[ M&#_DN@<1;XX/"4-,_NW+'S,Q((@V2=S?QOBZM>1\U7?=S6;3WO3:E"W$^1<= M]^O#:.(O4>0YF,3<(SYJ@=#WX^3%$?4]GLS1WNG;&0N50<_-QS(JY&^.DCGR M):?3=7J=]C8.6EE$63YB$"67U8#G)^R+W[II,9>^L,[:[UQ>7KI)M24F#B"; M.F^&PI$X@J34Y[L5NFZA+45T M'#7';IY:FMVR8G2/^6HP<7A@)C*%ZU-!UHH[B:,Z?(8FR_9BEBVH@G$R;=&H1HC!BF MP3T)/HAK7D639=T98*5MKD@K M6BP"JA%:#6=5WA/!S#S?J .0[O!(FEM%LX$'XO"13>F&')J&@O)V9C1)TQ\\_[4*#\7* V-:LDL:<\!3U/D MUV(TWWVJ$9H&=4QC[H5_X57E;91!?"Z0:IO4(EI0G@.@^L"OA6?J#L*^J=LB MN6C?,N09<"R5+090UTC^-=]>S5+(M!'K8I5#8 V9DC"C<0;ESR)(9\)8X_SN?9:6BFV&+S#32H S4I+03PB<%T@ MA;7C[WE#:@Z)>_-H#N-XC=AW :H[Y7PP-39L@/6%_CR0-<=^-7#3(9KF=X+\ MM=@_[#K=V13S4'>;JY%8S*>IH?SJ7:I;RI\Q9EW>$A>@<^AT?YG]"LJ_ <2F MS),/^$]VT8SJ6BW7+89+VXHBJU"T%"M]QMI,I6Z0VC6X6MUO_:6(C S/?!ED M%H-5U5AYY=K76(I99=3:]QZ9*2C79I_YNH\06PC:/S&ZX4NQ.5AY9&?\1-RD MMIC!(]HL?DVAE5I*Y#&)3_RB0IE#Z@Z9?6. #L0NDGGA4.P?M[\C,YHO==9# M:6BMB&-)9#6(IJPG(IC90N(+PK@!^&[%W4L@[V ^AMY"TW"Y;C%LVE849(6B MI7#I,]:%*G<#:;>/TI7[//)(',F_@,U>RLZ^^0]02P,$% @ U9''5N7N M1\IV! ^24 !4 !M;7-I+3(P,C,P-C W7W!R92YX;6S56EV/XC84?:_4 M_^"FS_DB,S"@85<,.UNA'7;00-557U8F,6 UL2/;#/#O:X>8DI! J-JP>8$D M/KD^]QS'\4WR^'$;A> =,8XIZ1NNY1@ $9\&F"S[QIJ;D/L8&Q\__/S3XR^F M^>WI[04$U%]'B C@,P0%"L &BQ68T3B&!(P18S@,P1/#P1(!X#J69SE6%YAF M&N,)1K4!VM7A)?I64L_<)Q@QQ&2TY_44VIEFI+O\[4D?BH:U )$#! MX2@6JB?'<;H.,($.=+P)20#V4<&_RS7)5.8:4C_#)53#F;*LDRHV]]!R.QWGSFL[[?:]U^T$ .6)0J9KV/+S9,QDI4_1=@Q9#*> MZ:]P>'!]P6ATHD_:$ZW(F+( ,3E;&V#-)0\:*\8PK$GGB;P>J!SLP2T8R@W7]F,;L@E,_Y!-M"*"^13(QYN:$0RM;ZR M":/O>%\UGW4C!V^@)54R2'WIWM"7">4"AG_B^.SMO@C<0$\N\]<%H%.O)>KZ M'3 $2TPX;FZ&[!<9:Z%K+K75T\9PLJ*DO,[+0YHA>"766O2:B^L_&!8"D2&- MHC5)5W&\0/E"7#/DKTY=>U!SL3VE(?:QP&0YEO6OJ: MZ^P)0VI<(+D*2!X^JF?5['6Q*)Q]RL'-L.)*_MJ2FJOI',L1YVO$KC+FY)1L M>@_W M&[S_,.3#WU!+ P04 " #5D<=687@GAPI EEB!R>YA3%.B'? V;Y0 M0AI 04A8"TM^_>N>&6UL!A]O27RJ3HRDT:BGI_?NF7G[W]G()!/JN(9MO?M; MD>2_";4T6S>L_KN_;]HGZ=+?_WW_/P3^8_\0\O;_TFEB?#UJGA'=UOP1M3RB M.53UJ$ZFAC>HD+8]'JL6.:>.8Y@F.7(,O4_%*XHL9259*I-T^GV\PR/5A?=M MJQ*TDY3%)C7Q$6Q4."@>9.1,EI0KV6PEGR%7YXO->3]G1M=1G7DPP@IT+$NE M?*8D9?)*.;_ZI19U)H9&R2>[2QK'%5+L:H5R0#CQ *Z#6[8Q4 M#Z88.E7R:;F4SBJQ?E:C[*Y.,NE,(>ID'=J5;*RCH+E#>VNGJ7 3^-(-#;, M:(B4]V\'5-7?OQU13R78/$UO?6/R;D^S+0^X,.W-QX ZD;5MJSQY6L//8.X:L'\#C1 M1C?UOWR=[A%+'>&WJ5&I6S"(>0T&Z:AF MP]+I[)3.]XBAO]MK:YV94C[]9EE:>E@KC_QLOS8[_]:O=C(=9>^]#/^5\H5R M*?/V( '?8X);!1&IHY@\,=5^"&;==+]]_GA[?5NGN:';D#]\G'[)3#M9!+.G MFBY]0@@Y0INT;[C(!MX%/.& ?F23V1D-!N568ZC-;TY;\\;H\NR':OC]O??G M]6:C3<[KQXU:%<3FMU:[?MXBC8O:$O '2Q]#.BT]> *)(/C M'8-6?(]PIN5"6BX&[T7/0C#U-4V#)\%U\)&#!*("K(9H/(@Q_I*0&*FS]-30 MP1Y09/D_AV-51Y,B;=*>5T$C(!_=D:8]4Z^\4OP-_71AL[^]#UMHU M?E+H"/I$<9X>4 Z9E,L>\N]6A$QTT<")?X>]BY2XA7. UUW; 1H(6TC0#7%MT]#)OV3V7]"":945C[?!K;(];A\&$4CR:=4T M^E9% QZDSD.3@,HD3T?1>GJ.*OE.6>OU.CE:*';*1:70R124?+>LZ2K\01&G M/M7 NBN07X1'['+**:-KFSJTO;EHM.O'I-6NMNNMMP?=I\3_#F"VZK4;4%2- M>HM4+XY)_6OM8_7B0YW4+L_/&ZU6X_+BX6 O[PQZ$M8OJCL YO)L*T6.I9KT MU[^4@GQ(,G(^5WYB#*^F\,)3,F+Q'V+SY+)YSC'( M@&(CWP$S!@"NS[2!:O4IJ6H>@<=*.9M[$1-29@_1$D:PFG1L.Q[9U\4UF&4_U-A00S]=#2A4&MK<84N%QI'37M+7AX8*)SUV" M3+$L%9$K653GC\+_-L9 '$R,'::-69I#5=D8RUB6?_>%D%]B1\ IP,#F*OEY MCJ%5&10S/)2##0?PY;QZ0!!]8:0K_*I?-%O1N"5RKHIR#*U7M='N]4J$?Z4&P;EJ1YGEC9Y&A[??"C_;#;LTSW&QW7+XN3L?^U5QS[5WUHF5ML^7-XUFSK MI[5ZW3C]+/^XGER;7X^N.]GEK_]TOEZ?7E)G.$Q_^=CZ?%ZM3^0F!A&7ONZ; MG;-/Q5+GJGYZ.?Y:_#FMC4JE/K0,ONZI79,&^!;^NF:;ICIV:27X$9\QG DA MH3!@(<+.8A)YG$?U/3NXP8,\[$XB%B1+^5A(@;?B]Y)A'<\)@(L%)_"^'MR? M4,=#=A(DSL,1HI=L29)S_XE3F/@B_B99^%_F_R]$FV+?LJ'_GFE/ YH+KM-3 MD.65KD/587H*>+LS@B7B) R(H*G:=6W3]^BCQ+(>.+S"0U?B7T_?=@HR4K:P M;@9>L?YH6,]*:['^2O=/0_?%TBO=/S76LUE)*;\2_N-,P8'GH$)^%.7[1&[: MX[GJZ'5@\LVC8\>>H#6=]-5YLA6,?-L9V_Q;+6Q=LWW+<^8U6Z=ADKC\LVK8 MM_235A\IU:]CK73TR4R#<S$,"GTWJ5.2$V?TV9]>F+YAIQN-6DS;U\TYKT^4%-F)VJ2 MTTHI7\X\#$%MUHTOEZ!VTB^_!T6UU5E#E"=HK+L%\KK*]W)'G1^N6F]9:;O; M^_R=YGTDK]Q.Y%4JIN50?+XH5*\&VFKV:/1H:+1:4O3NH]\U0]K6S<9JX:4E-J2:0^ M&IOVG#J_CQ QXF8DDR5.7[6,G^SZS:L,>=DR!&TTPK7H/>;J58@\Z60E;1]R M84MO%N3( 8NAO^QLB)HK]+1"KM?IZ4J^D\L4LIVN4BQVM&PYFRGELMV\7ES, M'7SL./:GAN>"WS OV6-S=G7\T>NORH84;JJ?K@8_RIGA[=EL?%-P)C^.3U=F M+B;R7/6JM7JG_F'B]5W_[*@U\_NQS,7OG8_(RU*Y^!J>>MZXK/R:CWARK.<* M4ODU(?$RXK([":'?(X91U76'NJ[X5 M(H]2$KYS)DA@C$4#+YTK:&FP); AVDI?^Y^_%YNSTHT_]+X,KFTUHWZ^?J8$ MT",+H&=V.I]!3+T0AKVR@5#-[\8XD7^!@8ZR:A,ZHYJ/E";=[AD;=>X1Y7CGN M:2<2>( @$_Q2T9UG6R"RAN/W'WFY%=H75?#T(FG%5*6M3*\F9_U:9GB;/KX^ M&7Y1]=-2=3=9)2O_T+!X\SB&133X,QN8Z6I@6XD$/T. =O+ER&CJLXLZ'0R* MA6NY/"C<+*\WVP1^)I]-HP_S>$O0MN'":#."O_Z5+1^ZQ*,F'>.8B<4&G2(@ M9$T?1051@1( PP'/_BF+NO[I4M.+@^J3KGO=/P';F#IBA8'#3&6X5+GFA GM M$;XR##0'VL#$5-U@H=4?/;,_?-O,DF+4!U89L;9TZ!O\"C XL)^C:,]*E MICU%;.)#Q#GWV4OI4](#X(%A#!>XQZ.6#JCV;,#VR#<]U:*V[YISXH)TX"("+)R/N-+0_QH1^81FL>/.O9)D" [Z'C8V".W*T\S@2N1,T+F$$E M9LJ(32]*JR%GMPP+LTN5-&OTM*6*7=LVNRI,F >T$U*,ZNNPGZ OQ;MVY3<-$AK/@(9M$CQ.!/E M8BYWN&ZUX:;5BLLQ*@$_H"P^ #*.+5UM^B;EC7.9O*#CA=6JN$AU7RF2VDF3 M9+*R! W?/#*E9 M;4 IK]$KU#T[U+=LT-)AZJW\.\A2$JADC>;W;^VF[@VN)C_[+X?D^;_1$,A(C&$-U2LY-:UD8H2?6)L=DGU.EGC+5\K_ MC2G_RJ$HZW''++:3!9H'SF6OEW P.K1QV[SYG/U\D_YY(6=&6+/X6IG/[V@[,(5YX;.:X+T$]/W-LX^7%+%'N<5$'?+;Q M\O8K1$%)%'A@,!D/Z7"M0?AC8E?4JQ446=8*M-S1\TJQDRL7M8Z:SW<[:K>; MR68RJMK-T\7:LK1^Y&0G=-P9UF[K]+C_Z?RVVJ]VY.4JM-;0^C&-HUMLN;1^WM.N2V?M:N-B:'QW)[*GG.@?1]AR:?7^]P\W1^.:_N.K M7/A^Z;A>?52;GUV+91#/6MDV7JIK&P=5;:6@J&WK\DQ%6IM_>:I0?1NWL@UV M&>)_J:H-^"_-5%UW]VQ+;FW-Z$."I^4G@A3*/M[Y[RRDK9 M[*\Y";F,E'U\^KEC$G#SWG5,086R%L_%GEW3@1$TB'3,+JE9SQXGQ$)LN\]5 MNX$^=C;S^5+J0EO/E4R7":.FXW/7IA]0P[6,B[R8A# MTQ.4>\NSM6&*6#89JPZ9J*9/-VW)M9EFH^EZ='GW]-GEV."X2/QCB5%(8RZ' M0TILR1=?KT_JWX]E_^3ZQ^?O%Z<]^T.P"'@3)9Z?MQH/07./+MZ?D^:$!OC# M:&[1ET8ULUSN%@C'P&.,=IEGSK.O54^_#MS;HWK&''VJGM;5[^-O*YWG&%%> M5%O'U>O[>,?D@VEW<>\U:H(#14K6!>2 L:+H%!49B+/H:B^XX]]088;!ACJE!UB4Y[AL5WE,,X M \G)>;*\76BT2VB6[*.54CQD>9B@L<'VHAOC7G285&8]@?Y-9U;TM6KKT;!3 MC%E$[\6ZE?[ U.4]X>2\55\]Y^O,[/7F]Z/OJ[HY],<.1R,\;-1RZZ,K5IU-$3?EQK-?X>"*=2=X_-/@[7T&DC@J*@[8%D1S MC_'+.UCTT>*Y__V?Q*I 51N" /$M':.RME,))CMV0HL81(9AMT_3?-&AV@-K MH:*:4W7N"G^@6):R@3M0">D%3]8B_+P;$ON-6'B.8IC<_;" MK$*V )9?KZAVRKELN9,KJJ5.-Y2V7DX,,P#.5',8K-9]4>FQ? M/MJZJM<:U3-R<=FNDV;]0[5YW+CX0$XNFU_@9_KL\O(4K]GA,.?UB_9#'Q#S M8C$8GK:_O!$M3%?<8);C&>(BK!=6$DOH/,/F(E(Q^R]]AOY?!- M"H!0P9^S)K8YH<3UNVBV>&C*.(8[1#=/)[ZE40>A0D=+$A_F1:8NO*(-8L"E MV!M@<;.^Z*V/8]LT%L]SC*[/$V=@%K'.4_BKBX;9&,N'S3FY]0''P1[E8"D9 M#L$M.QSJS='R@SM@RVFJCR/%,T'C7P!X-%Q(#B_SIL15>Q0,0@>$=ZR,E1E[ M&T 54\-A",RWC%+?UAE%0,+7BM7-_K!$JHC#Z.MW$$Y*;#4&TVG%7X/NH+%G M.XQ*>JK&ILBAFP:*> !3%:0L=064@-T(41)ILSL)Z#@!#2U[:@FBX;\9&:62 M-,0:<'@1(MMQ.1F.U#E.(G0=$JE2/(3FFN#^% M!COC,BPN!_A5;6! *U8$P8DIJ)<#:M*-'CL_$"C3L4?P;1AI0&QX"JU#\/1! M(R*8]C4U8"D^4PEQU&U+!R'8'4@ ZS@!@L!J[=M'F3! T (]T:. MJ49Q.03)*NRDC@Q#6[+':Y]MU0]C6N[T.NST-FPEW!K^@7/5 =X5O6FI!1*()PF9U'4T)2!4^ZU,1Y7;R-O&E8_M)]"B)YM*(;F&S@Q,6[,!@* MXUJZSV7=XEV@UJ5;J!H6;X*5;"W=LS'/#]2X],"Q?ZR ;&J82TVGMF\N >52 M.ERZ-UC54EMY>")81G",*1N#B=)JWZ$,T]C1TR#[A8LO MSD_,O6=""A#'5^#Y#AA'[!APN(\A M'!X+28L:3"#+<9+,0N+*4%XM(^%0> %BN[/6,M0(W.7R#2Y/@:V M8]URK1ETRBUC0"/*.?87E*DWYU_P[!2)0<^[=R.G\@LUP3X_ 0S:Y$BUABER MH0KQ4W5=6S.$2QKKH]J/C3.%0KJJPSRQ\+T@2FB0(BU5B\/=(/[@"&2-@_MCGH6UP'F&L*7,* @V#Y++=]*?^Z2 W MS$N:,CSE*B*S)0@>95?,;6\7(MSOHCIJU:(@Y"U!'FF_ +_U;R%$ S/E M>VSRD-"BM2-W,@WCLSFSS(&4>[YI2J3J,>N/:QO'0 ^/LQ'8EJR^2!CL7!NC M[>E0Z(2]%((SC0#!0:SA@C!*N4!# ,MT8)O,#(??* I23#UBR!6\SY'AC_#9 MF(+$\>:'A.6'U#[8ZQ0#6[%A^6/,(S,(N?[OD;KOV"%3-)'U]I/%,EN@[@T7 MS"@(6I "6KHKL;+Q%2WVRC*M;T .#G1?C[U]#&[[G+0P#DO)%OE! MEO$,0) M!,\V,@7]!/$62"CFH3)3MD>9>F<9E'A/*!18JX0PX(,\8S8P#-3G[0*E:_,! ML^V%NF"U6KAQGZ[.^3'OT)>FHH<+(Q!)$2+6R^+GF0D$1B;SSP^C,6Z =EG* MA5 G5?1=P,9A##\LTC5JA,G0_<9^#!'&7&S/"]K %IHP=0ZS3-@!\VZD)]", M$U]C#=*L >]I KZ4SH>XJOM7JWJ7Y/]=EE28\,<8%$$X_3#YS%P\-C3&F7#BQU6 ,6%O'PF)MVP/RNJ 8# 'R1,NYB<.\E]CB MF5VXQB FSWWG)!EO*_!G!7NQ^+SA8BX\X/_]09 /BMP*9D:AUX/38PF3BE=_ MDBLV,!Q*50.,B'K1>T(/#A8 +^I0M\,3O)63\L$8@Q3OPJ"8&V-@908R\&J0 M#9;>93_N6-B.7&8J 8961#RGB58-O">K.M1YCB[BZVM#6A$"F?&%*?"/?WF/94 MW_3N,^UQ[NS20!BQT)B( 8 S'P]%8 UL%VB/&0 &J'@=-]$SYQ*IKH#(B !2 MW?5"3<56_ 6,#81^?;0M,%P(D8O"V!AU?<<5X?\P<^ARYRKJK,M#&$)D\SC[ M]KXX3_KLA\%^T> *NPD3!P+-,9CCU@U^?2NPM3>L;5)!A?IIGF*YB>@D)1[8 M\VCP3:SVV7+&61$/[CO(LQ)H0>DB],PKZGF EH5)NY1:\?H>=G0:3Z@Z9&2X M8+TSFI@.6#M,&*.SB=W'D17,!XL")>J)>F'.)=32#+X 6)>XE)6Y,1-J.W[9 MIW= L#!?'!$)LF:I7CK3* 5Q_.],/HK9[O=$Y[P,#7H#>>PYMGDOD>L.&'SR%G\!G.579XU4TE7M8:./_; 7H9I1-AA:E*)Y'N( M:XOG%.)63\ SL;J]R 3"2@U1-.+-QS0V0:\B?UM8&ZME-IM]EYF*5BJ(RS)' MPQ-JW]N:HI*9#EY#P-B5N8U]7K,75OCP&UAM%96B,?.$ YA(FM@F8W160,&4 M?E[^3] HRG?$]40DNJ,L"#,N4!RRC%?D?:5$(1'VP9<7+5C;Z$L:'N/8<-'/ MUH(\A:N'P/)THNYC[,\T:PSN*(Q-9]316/$)AKMQJET1.$2EARY#O :&&80! MOG:(UUL)-]14I\*+X)6 ZS2]D%"&ZW'O5]!-TD0(^#V2&DR(1!>1R$";W,5* M4W2WF:Z*GXI)Z"0H>@WJB!$^/A:1M9KS6A;<0P=+A#2F,*)IY8B+X9WIH"6\ M'HV]6)I CWF;B? M\PE+HWB)KE+FXDATLJ) (YXR2^"2^7:XP/Z^C1L4-[ M1WS+%PN%X$UOBB\O#&PK2K1<#^NB,![MXD(@PQV(\+K+4O_,>P \!ZM75B(G M6FX-_02^(*K[>/#<7HBDC6V*"3Y,A@H%-?2N&C[B)\LY<\6E*.(3W/G MG<^T9H#_0U>HEE\QGYE]S6>^YC.?VC+_Q^(TU%\NU MQEPN!FM(5+9##,H(&,E/-:;=0@7(K+<@IB6Z%HHP]#_"&%:/J5* :\Q+;MDR M*T,7\@%;]5#MH>J02%73@/(QY\K1=&^\TA2XH 64:XSCRG&5^D@UF?/5&E#J!?74H<-.H@.F'GK]PLN=I5W7H4?Q:K4+(E'@ M-UQ*0ICXY_F5V-H'[N'>8_%#X-3&%T"D^%E%P1IUSGC@65,>&!+?@381";U. MY5:+@8JQQ4# #+[)Y_SD&'C.U4S;Q2* !]ZR8??MIIYM:=6VQ=#%@$Z%TXK' M _ <.2@2%;4 8>M1D5E8$G^_SO4$*9SUG; MCR_XIS'3(* )7J'U!J5;SWCS&CQ=7%? 8SGBZJ&8,&Z 69.L*IK<=N&<(>QTI8[5"3"B_&U6?'&T1*M MP*Z:8NXA9JFQ[(FA=F-K1)AW[7)X<-VU(X9FQ$>V216(^@Z3'WRDT\!&$UOV MK3_?2VRG$1]:F%A*[+;VJEJV4BWEF&J)++=68 M\Q?.1[$@2"(HE.$]/M0!'EN?T;(B%^+]JQ4_D4( MZW=">[XD%?*_!MJ71BB.'%D KR3E\X\EW/[QS!<3$Q_F192[3:;ZUX^-HT:; M7-R<']6;H36TNV!+;F;[' C0##\LZ)@#1?D,W>SP7&] M56LVKMJ-RXLD#ZP6!O(:'"9D0SZ4#0L#W= Q4%(D9;:AO+R4?TDG?C#C,3X) M&44J);*T&'C:F;^DXK.>%+0CNX04D-U*.Y0RS)Q^YDE,CEX-^L0S"M(POYB? MJXA(TF'\0W_=^K9W>.?G>+/#/3)P\.R$T<@UTABZE MR<49GY;*N2 -O] !^ MXIV.X16+B#9Y1#01]@_#J5A2Y)EP.[XC;;B3;95'304P)V!]I+_ABM,6M;"\ MC<5WUF^1)(4DH]XI9Y2RE+F'/'A1#*_(N5=^7\'O3SJ\-BLJPL6V8[83"*\? MVAA&3HFC2D31?(-%?LC7H^;9FJ.)N G]0N;FY<9W'A R$6N[X_#M9\S%OY!# M*7X-W-PC$OR+5>CE7BOT_M@*/7'X15'6BU33E8Z6D0N=7+>0[73S>;63SV64 M;)EF"ET]^Z2'7VP\9*+QX:+:OFG6'_KTB%U.Y'A1"F]Q]T"QRCG#/2"8;<+SRB[ )C91]G"GEX%J]A+U<*(!YKA]K&9@W:F^ M-[ =&.;#KGKZIY/V;*>QLRC#0L:'W4L*H^V/9,_+DO)+VNS;17!S9:FT;G0D MDU!R3[Z[\GF]V6B3\_IQHU8](ZUOK7;]O)7B"?#&14U:&=#Z7>=UF[F4-N;A M?L$!Y?'<\U]C1*_D]TI^OPGY/8'_]@7M CAP#7O@@D3/3GNNO\O!/D8?;'MWZQ RY0(VO9/B; MD^&S45IM8- >.:-]7#;5ZQF:. BC%E108YS H;A[RII\PA\9D'X%ZC5T_Q)# M]_D'#=W'XU4B:IZ(6"7OA9'RY8C_Q#;TU0'_J+*O:^MS^#/P1N;[_P=02P,$ M% @ U9''5MO_B\1W*P "RT !< !M;7-I+3(P,C,P-C W>#AK,# Q M+FIP9[5Y=U!3W[?O0:ITI$I5 6D"2J^)R!<0$!"07B)B 4*1'FH4!)0J74! MFH TZ9U(C4KO$(1 Z#VA1DKR\KOOWO?FWGDSK\R\=<[YX\S99^_U6>NS]MZ? MV<09XB+ K*>MJPV070$ ,M(%$.< 38#\RI5_W22C(-V4-)24%!24M-345#3T MM/3T=+1T= R,UY@9&%D8Z>B8.9A96-G8V=GIF3BY.-BXKK&QL_VK$S)RTC\4 ME%7G.P6<(6%C)R%C-@#")#\I"3[-P/^W_0D'^+Z])7T-(WP$*%LIK-^]I4+$:.U#?\F23 M>9N81R/XH+J3W604*R3[S"OL*BT')]=U;N';(J)BXG+R"HI*RBJ:_VAIZSS4 MU3-]8F9N86EE[?C\Q\_1"W#_GSU^^Q\8G)J>F96=029GEE=6U]8W,+ M=W!X='QRBO][]B]<9 YV7_8_Q(7"PG7%0H*<@KJ?^$BN^+_KP8L%)0W[U%= MTS"F=O!DO27SEH;M06)>=>=505D3+/LSKU%:#B&Y)6'P_XD+!="3DY&21\X"@('+!U/'@^!N:ZV%TC+[SF+GJ<2,5RW-'X4\2_9T M-^T?P5USPV\D$H&KDZ7(HHI.@3.I)@A>-'7@^\75ZFCEZX*YMHVZ3WBIC7G+ MR8YY4HTF:"\6JS@YX[-I/W_47PNM[>85>#?T'6S3,Y'D5I?BVK#O,SR9@'>M M"@B+P0S^!H*ASH6#1F7O&[P;'7B.U MB)M>5?[]D8M=R)TL4NGXS'C<78,L\DGB:53)<<&Y2>,+/!'X!.]1^4T$UG>- M.L 7'\ZJB0!#*O85(2H+#=+X*O$X&\M6DB0"8%QL^'FCYG+JX- M&9^Y%/USEQ$F IR(C"7LZLVG+Q,%^YL\>LS]##R"?T0.:ZY6L-OMY0 MP>G-]1T^?_GI'71^>8U<#.7JRCTJY9FPES=UOO^JO.!7@$7'L^J[1_5Y&M$L M>3WB]82Y)(4>Q)C4SBOZ/F\5>&"LQ;Z3FQK!;F0QY:H&+AZ$?X/8.$_=C?WE M[2_>R\WD]PPH)P*TL.WN')7ZM.7NEKW<2DTZM\0=*1.'ZSL\SDH7+@&INR$& M9N+QC/DQJW9NQ0ONQE:HT_=U5;2;-2XJ4T7.A3/:KZ<5:\N-PP(9!NX/UWO" ML:-P.L3&%Y@_$:"Z1XK\HV\/5'0+H?I7WU9L8:?=HT:L[#XJL58F*O'U3!=RD*[] M,U%^/B+0&0M?-MTM)0(RYX-I=G$N6[$(+"=!)W_4LN,ZKC&J#>HZCH?;CM>7 MF.ZK1XP9-&[7?0Z5KU+#H3J%QA]^[.9.#Q!Z^NT;E:[0$?E4O8&\SY#R>+:R MEX'8@ MZ 41>(/XCP@@_E,$4N%.51%[G3H]3(PKGYGPGWH)C3&R0&#CKIC5] M(_E=)-PG434^@];0:$2%;V&TA#R$MLP>WLCP=-V/9H@"1/YT5CV"B/-L8$27I9:\@@)X35Q MK$:1>M1,>5:Y\-8PPKKVQ&?Q3ZO0W'E\3?0A'.\,C@ ?&0?+DX I(?#?QK'H MON$HPMV)<8-1-6B>2^:[7*^IZ<UB"[?B1A!7/,_T2VT+QW8W6][].V']5[=[$ELZ( MXC\LE>>>?>@E KVFJ0^U4"8/HRW5#)P.QXK$I#85$.2C&^5&3+#E[AS)ZR,7 M&D7;:J\NKQPH8\&+0E/SULYE!9FO2?DU'QED)F?8IBFN+CA=F!5DQ3XT==WIBM5!DLA%[Q9S/WB\ 8"/9RP*&C]?J2UM.$H)D_ M0K_^EMZJ<_Z:4_+;.(4G-O63L2TR&B2*5^U4E'##,+$[H23[G[Z7WL^/^*E^ M4DL>/372IE.(S^^QWT 5I56\-*3LC>LRX ]1%+N5E&*S:F1J];B,2[PFW#C$ M=?2IM V?4O&:0&WMO MW>@?F]]A#U<_A N67J>G60Q3C?8W0*VH>,<^0?D%@=[5&6O)RJY6X44;+S[N M2A"Z1^ ;&66'20AMTJR>CS[0K*LZ9](@ ODOJX;T_JKU7RZ="9[9O$&LZ O@ M](]H3YC"4/S92T8,V[GL:CJ.5'G%3@-W? Q4=OVU2EPJ9=ZFXY.$_\Z$J$L, MJ?$L\1DA%R3&VI0+>M== E.[YKJ*\Y,GYT:?7.DY([>/PT69Q?02I+#[W9 K M!9 -?GZ'@DU= ;L'N#G6>5Y?&=V<(/'UO$IN:*KWY0(""_YY5MX5BM*GYGPA M'-!>0=G1KIS;TM:<.7.Z/^N^;7[Y;:\^ I_G ,6$"&HT-;1^1R2-B7+S?*Y6 M^)$?-\K>Z32D,S]L#-&]",6N=Y_@;4KL\A&D:L4][%\\CZ:0(9_ MR2^#N7-I^L,^FT:UTH[M67F6;K"44:-%E7$H %OO ==3)\@;4<):'WU'8-FF M3(;.0BI2'M^.94NX,?W:H8F^D\"$HQY4>XT/YMF:"^2@1>$P%Q-)U67^K6M@BZT;$/PSN6[=J+E#H5,PW=E_KPRT-= MI>.\+CDP]WU\CDW-\X8IB60T-?L9])R<"/QJ=LX]86XG J-]"%D1(I#P ;%= M )>%?(5_!U]DI640 0)W^[]9SN-H3I(2*- WSA. J,)/,,<=V-K[I&G.[)R'_U'F M@TJ?L$VZ'Z%1FO\T-F1@P@AC6W0E$TLOM"(*'W=W7&=+T,,R&NH^&PBX@Q3* M-0F!PCOYY2 M\4!^[5Y03.)I7/#%0(E,C^BQW!=*@#&LU2,)&8,>O,3'/.W%TW(X4%7ZW M.1U+X6H+\ A;/G<EPL M/Q&X6]4.DB=,(IA G+"U\ZXSBVX[V1Y_%>^_%HV2; HXH:9?<7"_WO<_*;"R MB4,22:FB0U*FZ>(Z$VO*:8)7K;/I%?BF4B9RDHQKXAH]#-R#%9>8.+=!9#B& MRM:E>6T[";.&IZ-_[GLVP7V1.J8CI8O1YZ8G'_&STKW2,TA-'$-,UE7Y.$,Z M/A,4AQ)CF.8=R%YZG*%JZ?6J'RDY, @>4N[OH^3=4RD2@Z-FCZ.UM6.37NO:X98?L9 .NY#/)\9!_]L$-3 M>;BHU68!YPFFI, )874K4(*]XI$6IC=^WL#JU(>^)/IBBM%EE4&)AJJVB MOAY\%RLNZ,FHG C>S[/P6>0QJ:%XSO.^DQHQ)''RBL"^'Y':S<3@M/3VYZVN M.PD7?F5T[V!ELZ@^7JV>[TOKNH;)N>HG?O45*^>YBJ%(T,UVO-WYG:T%(5R0 M$73I7"(F9H[B,S,1>(EJ8@F?7?W#["^)-+8OP.HLO;7CV.\ER(Y+5K9Y8J(4 M4>%V_PA#E;(N#9(XAB:BU;_=WYK[\(U?SA@7OBR5L?CI37)7!_/=;943ZE_J M2VN_1TYNOG[I,/X>&7BR=:;"EI886++1'HA(ZU\+94H^L3 MCTL87@ZYG KN=UCFD9XE I;X_J^;'$$[DM)RLSX"3-U='7DA5R][Q$%;;=^X M2I8TO.TSL%F+.1F+"'I!:(.Y]7I,/8=BRT*UMWN-KJ_/NO?2IVLLNJB8$?%X MB90Q$,.?;7B]3G2P;YD@J32<1ZTJTUV)P-9:^[G"=!/2FUOY?LAS=TS[6C3; MWES2J$+Z A%8:E=_.'BO.M:!EK6MF$O/HW4E>A5AH_KK-'G:\M-R9POU)7 T M?$&1<"$QA'"2OAH,:L ;8'@0UYS/W+,IZ\N3YNRUKFEZ,OPT>>;$=]]!ZK+U MP8$AM7(E.<9B9Q##Q''Q!*?XP7&L[6;5S%: MP?(^/RS9"O_6@:,,$\=I,'HT,T6X=Z-6VI'W<,?\IT6 D/#[ZXN,8>T8#QK\ MB]?)3BT/YT?MQZ3@]^R#L#$$?9V^X7-:9_29!OO3X"=8_K/MC9ONBF\R%GPXU%[FTZ5>U,=#7=[(=<35E/^W"CM,X]N M3_I:]+PRC1#B[L\O?)D-XH&5_$T/92+1#"D6\K7[1/73\&F:I=]W<)SG*7?5 M!\0KGCDK^<&7^WT"]"*IDBN3\KR@@B^U"A/.A>2G)RL?Z1+;9:X*/>&7QEL$ M815U6G'P;IY=;1JY.D5_ DMK6]):'V&6ZH7ENXC,ZP_"S#XN?B2CX#[>R-+& MYRX^>:F%&)&_5%) \NI3C!X)SEM7:.\6-K]L)1%DD$N?1=QG<>N)[_<#/Q<( M&\3&KL/*Y@D&%:1:.+HJ0!LL6'"A29((/0@.6+)1_;2OOEVH&VUO%<:JH*XV M4BFZ4.]'Q)^A@1ZOGBGSF"H\_"00GXK3'A'8J:*PWC3G/MALV-+3\)4=9"UJ M<\Q++4B@:>-4[.6\G/:\X8_JCK,5LB5ZS>+DR3K[ON+?/RG'*A722^8(7+6I+;Y,?C M6?GP3AOEB]>C M-C;(B]O'(Y$YSY0E/D;#.JL>C76PXV4U:VS4P5W6PMG?8FGRQO/-D(C^P6<7 M+OBWI3 1C7'7-G4/!G1,L$9PIGDB^U!P84;GR\Q'7B9R%E[4=E_\*UW&3VRP MA")J5+!#!3ZF3^4B7-;%7Z6]][O%_DHOW;=_"KZ3)YC:Z8G+>+X+R#4G L.0 M5L>>5.>I NZFZ*%4!;30C:J&76V<^<8*6B[[U+D&'8MXN4^[D'&<2TN2'C34 M,;>T@T*@W?CZ[K<_,N5[O+Z&'K1\CCV02(3'==S"H;O 47XJK+W%>"* - YX M@!%>2&-&)OH'LI'T]]L#\LE"C4$W%SC@:UD7TRYUB%F/9OVQ8,.3#5K-@[ZE M L$&<1 YG<8;AY^?NY>0QF6TV:Z%7&AS"!J-[^^.ZV+;(\?R^_]Y@Y'\+MMMSS)4--(>KQ.0F=I?\)P2 MTRB\7*[#6OR D,-XC.Y:.W&DGR9=3%M_+;TV;V_7?#Y\IY+NGDBNT7V),/P@ M]MP KU%L&VR*E7P'XI\\>I"N4I'V.8S'S;KG+FNOG'Z$%'.Z1=]B_W3F*Z11 M;$M#',YQB:0 @Q5E>RK*9W0Q="5O;DD$K-[K=M?=>'%+6[!R@K_^3^A8 ;CV MM =R3F8/W_A:EEZ;(L(EX44(U5&GCB_ZT&W>,^%EAFIQ:^UME1>>K;!(S=SP MAG-T7-\BR$\M3LO9G:8U^GUW.U."19Z Z$JL7BUPVK%7=OE"%[&5/].)(AE9/A2Z5_B M9*I^.S];M#1(JU5-S5"A0D^?3L*KQ69T?@[7PV4MP>CM;'AL#$X)J M0)%I),OQ4\0N,PW_BL7OEU?[65],(8^BR"?CZ",FV_GXQ>8>)]@Q+ZO])!&@.,7S2DFYAPJ[-!"! MYO"0M.AX) M*L&&28I<"U=_]K.X)3B#\P(]=BTK;U-AV_FK\]2F&X4FWEB;*L3(*RC)P.>I MDWB],F' [S"$"%0)=F$&IF"\K-WVDSC0$1%H94@)W54%!UP6A%\6$&0ZL9I+ MH7F55#J3ZZ3(C.VB"=:VWU5U^2;O2X6D\_4&FYU?"^;.Q2!ZSA.N0W^?MFA' M>9Z4"C?][9@MN;?P9;UR++CO=';;# Q%<^*CED5V>4AU999:7KAI07([,.CY M=>%DYX#W1ZX)634W0/6GZ$Y$)#>\\O1JW!:E-@D!NQ-X@ ZI[>+A&X(TDPVO>H!O<@/EA[=*M+&+9T M7.[V%97:./OY=7X?-Y![2Z6>PN&]\[6E->'X&A%H@J>&AH2.0ECD/?A"9_E9 ML=V:OI")+DAUY2GYY<2I_-E5GT[)KR]O/A&\9J31&\@& M/7<>E"PH_IO+D_D"//O)5FCE\JS:*U1W+C4$==;0(O!^G#0C]*"/1Q$95>/@ M&0&"0?\C(O ]8I\0+_\WXQZ#6B%OV(X&WU_YLU?_11^U\=:29A/I _ K'#GA M'](*P L7$_A'M?SAT X+V[4!),"X,KU*O6N R^N0OS!O1]2G(**._LQL0F<+ M3 _UCQ,CX?,TJA:HW$9(+P\Z"D$-KO49P]GCD[R_9J4JW=/\7M<$*B_P&/VP M"\GJX,&2PA;C>ZGX8.S&N791B6%:PTA\Q,SBJQ'&PA,@'>)R[7"B,$U@NI/!:2VY*5-'(W2XK7+C:P/<,(=!.3Z[#6U0'!!L5(2_- M!RO6PYXD9/&2!YR*\Z/4($&CG?R!&!B 5^O,%2B)C1 M3-TVW<]W[[PE]MZU15U^?69Y"5UGHL!OV^$],33'PPQ;3$5;U7TXR=^WE&F[ MZ>_^B/?<-/29Y&Y+WH1F+%8?R]JV;L/TQ?2STC-/Q@RT6J&CBHZSK">,^)ZA M+QMGUE<\F^L?8M6'J*!_"$+!'/"WX._3[R_4O6'I9Y^G']LO#-/< LOOW>0Q M5=LU,[NN_MJ0RA.B".]VN' D GD84NF122+P\\_PR)-$?#*.O+O1FO.]FBFH MJ'#>3=9&O4U4 $IE;T:VE,+?7E9JUFT:V\Q6.6X]\[>EV8-YN>PQ['==JHIW M+"I!QB,5_0TN:9&QGD;-'9%WE .^I+%H)\SETDJ!^"Y>MD^Q6!W!66NW% YR M8A3Y@Y^?1=Z,JB4)8%4!$BOKB$ EB9$;#Q!68.?<\,0+*-ZH9&/T%A%PLTYH MV/1JI'1GYI4*HJ;\2 3:Q(RF=9WFB,\"MT^C[ ?O\(L%@/3OQ%4<5;@AWD M8?=QJ$]\VTD]$@:^9U<R>L/(>6SJ.!@G+0>?,Q.N S6(J4W^C(&7XUC MG%OR>"MOQ#QXM36'DL5J5@3=VN)UC>N)O]1.P68R"L$GA_Y+:TD$IGL@9UQ5 MDWQZ\P01PNBO8KM%)P&FW2\3H0-( LA7(M63_AW<3S3U)Q%P>712E*[;)VL\ M/RN-//@S'K\Q7@:A4T%WAWTN6DL.:[QL0\6=V5\R%BPF=/Y1R?G,MIFF,G!F5_[; M>[U0[\VOHU?2":[FG+O4&#O-D$]'NGA ML\FSW)2)O%VL62V]YN4*RA,RWYYUA&CE_U-CE^#[_?OM_];,&' MZSN!\^.C'N -OC[<\LTCT8O9B*6S84S0H5U&16[_?52U-RKW7*B7'?'C4H6& MY5DTGX[IAUOVB1$=GRE/?@!F01;B%S%0,,+H]]JU'^-%J6VDV?W]*H_4J$L@ M$9@;4@F0.+X#1?/OE:NY5<&@VG@X!LPVG"\GYN_[E(V!1EKCKX09B;!/ M;1.!VKW<=@8';4F)!K':41YJA7\F^&6(IAX<0 MG= #O^"O(@+E^)W%?491L=$RKJ9NNL+^[NX6S785D M_*2SXE_W\KFL%9X:T5"'ES0C.,ME[Y.0- M1O==D)W#5__@69>,WJFIP_SMG3/-ZNOPRE>T8JG(9WBCUR^$L=1ZH\&:KS!& MS%!K9'R;P4NFV7J&T,6':;&AAQI7(N)OA3Q8"9R$Q^6R>$CVA))A@V.\<>20 M][U7B@?D6OTP^INX4Q8R5=(FT>GZ6H-;;TL]>XOPI>^K;.[7%5RK>%UONT,] M RNGBM"M>Q9NK8HAJ?4]E\GR[]4T\R]T)G;?0X,0/%M)?=UY)HZ=%YZ955^W MTTX$&A8:OPYL);N &!N&5P1$&YT(P^^%.?AX<.LKGD@@\&VNS M\G_%DEBS:L)%97F6@XCS) +7VEC+8 4G'W&WJY?\XH)?+%70Z4W4Y/'4HJ-?=RN(P-!ZQ]*#RA=QX:E?EIZC]9N\&F?MIWJW(XE ME-QW1>*WIGRN::E)\0F9_/M1II< 0\?M#0AGF[+^R["S^0=R7^3K[;WCW71C4*,UA:3"H-Y3^>T9,1\;2KHM^T*.J[P*. M#/);TN7G]0)+!=25QE['O@HRJ= MX30^0SAP9Q4BW%^Z)W1[, M\70^?UG,M-EUOORXTIQP)5@>V]BESG\L!S6KCG^IJ'@6M[)[YY2>6L9([5WM MTU=I2KS+[+TZYV9XT)%:BWLZIMT%&73'.C)C::XUQOF'D'N\UB.5%5Z6SCQY M@V8S9\6_C#[?'!VXN6B]4E6"6CW$W.6.:9GK63[?NGA@U?//=VT>%I9_TPWAHYI@FM)6A]R#BR0 MY%)YD EIV>U9B@]=0S$I:--$CZE$V"91WVX7[./G MJ,$A(GSA3"[V'B>AI5#A;&32'*3?5WS.D)&104OE]8E7G++]NKLL9[1EF[JK MF\#+_'%=D1J7D]8@H22]7Q(2#%A[HW ?5B)@2%(Z9Y+0EVV!Z!.7NOHP)0?\ M!]PU)[K>G 7G)$EL\^/1WQ&3D8Q<5V@JU LW^P[B8P:6+.^ I!IO\[>OB^1[NNSN M5%56O1@[KZL'A>5'2Y1@F=(0__4HJ4QB+D[A8.%@+$#2?7?%*B^'0QS7\KE, MC(_F!N_T-A+I$9X)1QI%-=I?[VA)ZAPH]88&<._=?92!ZH7]N6O)DO@1^3&@ M*B&+<+46LXODEQVE&:9 #8 K@O=4Z:R+W&':&Y?]X4U1$C]6<\WZS!XG)8\6 M?PO]D".(24#I($%2HQYRY<7Q(!,)"I$\05U$2F;DM>^W( M@KUVM/"I%#*N\_SQQ?W&4<%J_7GP;C7J,E+=9W.4S_C&7&,_I]+\>.SE?O"A M1?"]%8;!]N57($ZY;!Y)[[I)I-F4PW)O2FT>\5WXD]C&Q;Q$![&XN M)Q$86<\C HMWT,LZ_]FYD1)'\U(P@D!3E/4Z9;E?S-3E%,]/!/!,QZ7+U80) M-(OC:$&-2E%AXZA-UL/C35?'$'.EAS?RYUF:7C^S.@0=*=P#'[?]=2.2"Z#U>G1*!3NI,;+*+X9.] M[.DFTNL/HX]O ( *V(5\)6W!_M.!42>&%#Y7V/??84;<3F77!;V%"WO>[LC( M_IU&@6DZN)P1U*$"SO9L8ZM):W3"STYE ?X JQBU=XQ4ECFJ](R3E0U+/3\R^B=Y+]U+.H94O<%@7&WG&-Z_YU[_2D 8 M3,IMYL[46.R;C8>"2D+,&A37& *&?U3-K'?E4JAI$VY&$TY[N%$%6FZ>@24Q MKN5W>UET%@0%/47"[O<9!*VR[_R.4#9XXCDID&(\6#UQM[;3Y-NDF =_#AQN MXS%Q6!4/)O=A2@"Q&O#8.%>\:$P?KD74([/<;M]]^/-&&"-M3D?/%:7<-^!J M(A#90;&=#.TOM8-%V3FA:-SW"BR3%A3.YUB\(]7IKL$6'45 IUJ,$6*DP4ZC MC!21HUWZ9(9E3XK:X&!54*FJ["!(]8("2U*I: :;SEW__A@3.QWQEW=IS34'L#RYWB)K=^BE9E/G$?-OY;#KDYD%?E+//GR'@]_@%_)0/9K7*MNA5#M. M37,UNJ8E9GSRZW!F!RVA.Y0;K[LL 6&UV_8/%9YP_0 5RJ&(Y.(-4^OZDC1 MIO3KQW;L8D(HSC]";I@/YFB*)=2Z2AVU:U,U-KW[[&ZZ$<3225T-3+6SMZO( M;6IUT6G#\ /3/)\LXD58S7Z[3 59H\JL?T$KLXU2+ZX2 8HS+#S\P@U::0]M MB6]_]4*IJ6%<*C^.-?!S<69__YO[2EUA.LJ\%A6PPR7#VJ!E(5QNF)H69V2; MX5298V!Z6JY+S<13( M^HJ(AMT^'EA-C[LKQTOA+/(O[%F5%\(X^PC,I6,/A#'8^$5>0],VJ+00RD&U M-V3S)@\TRC^M'?<[@EY&\^DU6?MF+4AUE+3T=M6"5_DPZZZ=^7A+K6U96O^+ M?JB5]5:_3N4Z.;9QR36'(M=JRC?NF=$U?*MMHM!$?8 #<^03KGBN@NLL/6\^ M2^D*)>G>;FX=#@^]@RU^+Q^GN82,=0L&%V]S2H8$Y+N<>&>SG'[)1& A EWN$()N 8'%(QYR!,;K$(&KS?"_M]NCHW,=^??W7^:B4N'K M\^ +3B;"/S@T7JM#&3Y"*AN!B]NK)$9G%BGN#)-^D:\L*X4A>BTRD?'2H*&I MG)MU;]T0-?1,:P\D;_VBR?LEV93T5UE^]^@Q%@MG1Y>Y%F5A\BJD+$&X=\^. M_.O'VELK# M+U@,N]]UKEIR!'6V/SF^F-LU.7O9U-Z>?#[^""TKH#'B=Z7E3+Q FR5X#J$( M'UBO^/1,0F/,35O:EZM/[.R@""ZQ,,\DC./L K,ZV]^;;#/ 'O8J=/ W3T6# MRHJV&JCV?F->/ Y;>M BY^5&R\C(X_3SYZ#[A23>3N3-ZI2O&\0JO:?CSK2P MKJ^DM>4[\4ZV\M>]7$(ZUZZ\;A8AI4I^8?1! 4U_!AQRH_031MSX1,9E2K=5 MHJ[B^2JTKKS.(W^G8CT4A.?Y ENW2H!$!A$!>EB-T,$RCBH.DNWBKQX%(J-!4DOSLYR_X<9^1M@^4I1 M?B7;,D/L/:[?^,("XXT&7:'T?%WAT!:7I_C#3FZ+'OC5+1#?%"; YWR"=DU$ M3,B5YGDB5\BT.>V/DQL6GVWPU,L*J?1^:;ELM3ZS%]%)>_LTA&.1O.)8Y+.T4O.)9&(M]GKS7G%Q_U-Y8T_$31YI3 M_P$I)!,!88%N( CF0 3^WLY@ZDQ@QS=:CU6&WL*CF%BW&(#8;F?9I=]R^ M-FE^6OF<[O?QYM^PY_1O##WMD5HZWZ/,T8/9 JBF"*RHUNGC,.AHR7Q@Q8-H MTWZ6DG.U'Z$2$A$#!(, $I6*C\^KT'*LF6/X]DX4_:Z:G200)^O7S>H M.?A+$/33F*>AB-CG\>D)BW28)R)U+#2".UQ=2!>SL?19J+IP,.3Y;Q#&PPLCI MNXY?;N6_!,R 4"53$<2BL*O:V.\46MNEL[1ZI6@NK9Q()=VR'DMS U*'Q0085=W9H3P/')0FWQ/ M9Y^:T;MBFGL;.=U[:4F43X6-C^OE!S7Y$E,_ MX>'5S #,4?O-U/]A]^C\5=BEXW&%_9*G@NU6F&]C[_]VGH\&'"N(&_B/V M9S.E)U@.^LH10(>R,3ZR\.9*(+@43?0AY>*0&X%PAW&JE9XM*XAPQ)=87)1B MQ%S,D5#'8FX9*,()*1KJE,,2!)B)&IQ:"0 MDQ@+L_1<^H0ZA [AW@B,%+9:(H32,]'&Z 5"SS/LO)8)7%-+]D-SNWD3$D 2 MZ?^J.!\RI%>DD27W" -;0VTR;7S\V15,E.5*C*78Q:?"AK%>]DH\,L MEQ$;\ERQ"VX,K]QU@U8U=H&E7BS%%#/)JD[/IU,9"E-E9;#&7U,$TO2'G\(W ML#)]8386PGEOUJ4/OR,_I++)$M"C&J08T+:O,Z.700 'MX/G2TY@ PA75A.[ MXL!D2^UK75,EKLO)@R14H#R9 '3E88P6R\33#W3B?8IFOU[.IG".A=S&$*07 M)2&0Z14V \E9\ 9 8K625%) 5\&+2%"9=*\!V5U &=C124^.MEIFY964U(/5 M,_XZMZ+5VC 64:Z(WW21,D%$Z.> '3\'[!6-DNC//L8[A;@[/ 8$670:NNG3 M6))A"6%DW+I;&+K5F;M15)Y^@27'I?+L_*AFD+KR@)'IAIY>;@RM&HHBTRG[ MI$'E>\&O *!:08R$^XE^W7?ZUP4-LYY.$FDMM=S7C(3N$28^=MH?#NCU>-#K MGB 4U(%]U!K[>[N51P<\22/7C,^*]12Q2,R%TIEGL-OC7:7@ 1HSY.2F9:%P M,=D@H69)]]"B^40)EI3*($R&OE@+!=3WS1RB/1(JV,)GJ09FPLJ*>-$S!,2' MQ4 003-L+4@W5]PH/UIAIHQD.4X:?O-1IV'Y*:2DDP4T?1:R07;:ACI;K@8: M2Z98%BI)6 *_9W3>0*?01D4XV8L"1IQ%&J=S,FDUNIAT-9-9KH0?6<"X=!?" M4J]WQ4).\*08$Z@N8+JX#FE,0.QHCL3H(#& Y="[,DLDF=)+NS%B[58:6)X) MG2&\-Q:^:O".A]WC_FEW^.N(7::*@I)J_^"-4+"0%GG#2!L).E+8ZP0?&I=,;9A(.:&**,LB4NT#Z@8.:2B M,,2;R/X!:K$0YD?IEY0*J@+3?M/<;^UM[W?^%$\07J++CS\=O"WT13SS?.*S MP?J+R?F?U(?7;E@!^^(U-JO-:XH/REJL^[_.K:*X>Z,T:O,)=_VAVBDOW?X= MHKQTYV>(S9\9,DPVP03GDZN 3]$XVEPM^-*6I;B[4]W>_;$ST08GO_)9?OW> M#Q?_GQ]$GN6'A!?(KEN'O?.S<;;_9NMI#Z5 MF+<.+;E<#4N7?T[(4OKZ2M$Q./M[?S0^'[+!V6^7@^&@/WK&+,HKP2YD&.(@ MD>H*ZWWJ8D0=]IY/PQ<<9A8RA)J #7K#9T7*]G8K:#9:0?UC??\/(26!^]5L MY?[/BY6MA);[C/*]6M'_WG?F6D;_K>W4BI_L_?\!./P/4$L! A0#% @ MU9''5G5MQ8-V P 6@P !$ ( ! &UM'-D4$L! A0#% @ U9''5A&1ZO5I!0 [#L !4 M ( !I0, &UM#DY9#$N:'1M4$L%!@ & 8 D@$ ' *IG $! end